Format

Send to

Choose Destination
See comment in PubMed Commons below
Health Aff (Millwood). 2006 May-Jun;25(3):707-19.

Mental health in the Medicare Part D drug benefit: a new regulatory model?

Author information

1
Department of Health Policy and Management, Graduate School of Public Health, University of Pittsburgh, Pennsylvania, USA. jdonohue@pitt.edu

Abstract

The Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003 represents the most significant expansion of Medicare benefits since the program's inception and has important implications for mental health. Medicare will become a major payer for psychotropic medications through the new prescription drug benefit. The structure of the drug benefit's delivery system creates incentives for plans to underprovide medications, like psychotropic drugs, that are used persistently and are associated with high expected costs. Regulators have put policies in place to counteract these incentives. This paper examines these strategies' likely success and suggests additional approaches to be considered.

PMID:
16684735
DOI:
10.1377/hlthaff.25.3.707
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center